David Lally, Aldeyra Therapeutics (F), Alimera Sciences (R), Allergan (R), Apellis (F), Apellis (C), Apellis (R), ChengDu Kanghong Biotechnology Co, Ltd (F), Genentech (R), IVERIC Bio (F), Kodiak Sciences (F), Neurotech (F), Notal Vision (F), Notal Vision (R), Novartis (R), Novartis (F), Optos (F);
Judy Kim, Adverum (C), Alimera Science (C), Allergan (C), Clearside (C), Gemini (C), Genentech (C), Kodiak (C), Notal Vision (F), Novartis (C), Optos (F);
Michael Elman, Allergan Pharmaceutical (R), Apellis (F), Genentech Inc (C), Genentech Inc/F. Hoffman La Roche (F), Graybug Vision (F), JAEB Center (F), Lowy Medical Research Institute (F), National Institutes of Health (F), Notal Vision (F), Optos (F), YD Global Life Science (F);
Oren Tomkins-Netzer, Allergan (C), Bayer (C), Notal Vision (F);
Yael Alon, Notal Vision (E);
Elad Bergman, Notal Vision (E);
Anat Loewenstein, Allergan (F), Bayer (F), Beyeonics Surgical (C), KHB (C), Notal Vision (F), Novartis (F), Oculis (C), Oxurion (C), Pres-By (C), Roche (C), Syneos Health (C), WebMD (C), Xbran (C)